Curated News
By: NewsRamp Editorial Staff
April 24, 2025
Tonix Pharmaceuticals Showcases Positive Data on TNX-801 Vaccine Candidate at World Vaccine Congress
TLDR
- Tonix Pharmaceuticals presented positive preclinical data on TNX-801, a single-dose mpox vaccine, at World Vaccine Congress 2025, positioning itself for global health emergency applications.
- TNX-801, a live-virus vaccine, effectively protects animals against mpox and rabbitpox, meeting WHO criteria for broad application in current and future outbreaks.
- TNX-801's efficacy in preventing mpox aligns with global health priorities, offering hope for improved public health responses to infectious diseases worldwide.
- Tonix Pharmaceuticals showcases TNX-801 vaccine's durability and effectiveness against multiple strains, contributing to advancements in global health emergency preparedness and response.
Impact - Why it Matters
This news matters as it highlights the potential of TNX-801 to address current and future mpox outbreaks, providing hope for effective vaccination strategies in global health emergencies.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) presented positive preclinical data on its single-dose mpox vaccine candidate, TNX-801, at the World Vaccine Congress Washington 2025, demonstrating efficacy in protecting animals against mpox and rabbitpox with durable protection lasting six months. The vaccine aligns with the WHO's preferred target profile for global health emergencies.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals Showcases Positive Data on TNX-801 Vaccine Candidate at World Vaccine Congress
